Introduction
============

Osteoporosis is, for the most part, a disease of aging. Age is an independent risk factor for the development of osteoporosis and osteoporotic fractures (low-trauma fractures) and the prevalence of osteoporosis rises dramatically with age.[@b1-cia-4-121] According to National Health and Nutrition Examination Survey (NHANES) data, the prevalence of osteoporosis based on reduced hip bone density was estimated at 4% in women 50 to 59 years of age compared to 44% in women 80 years of age and older.[@b2-cia-4-121],[@b3-cia-4-121] The number of seniors at risk for osteoporosis is going to continue to increase with the aging of society. It is estimated that the number of people in the United States (US) over the age of 65 years will increase from 36.8 million in 2004 to 54.6 million by 2020.[@b4-cia-4-121] During the same time period, the number of people age 85 years and older will increase from 5.1 million to 7.3 million. It has been estimated that in the US the number of hip fractures and their associated costs could double or triple by the year 2040.[@b5-cia-4-121] These statistics are similar worldwide.[@b6-cia-4-121]

The risk for low-trauma fractures goes up substantially with age. Hip fracture risk, in particular, rises exponentially after age 70 years.[@b7-cia-4-121]--[@b9-cia-4-121] In one study, the incidence rate for hip fractures was estimated at 1.6 per 1000 person-years for 65-year-old white women compared to 35.4 per 1000 person-years in 95-year-old women.[@b9-cia-4-121] In 2004, there were 329,000 hospital discharges for hip fracture with 125,000 occurring in patients ≥85 years of age compared to 116,000 in patients 75 to 84 years of age and 48,000 in patients between 65 and 74 years of age.[@b10-cia-4-121] Low-trauma fractures, especially hip fractures, significantly increase health care costs, and contribute to an increase in morbidity and mortality in the older senior.[@b11-cia-4-121]--[@b16-cia-4-121] After hip fracture, only half of patients return to their pre-fracture ability level.[@b12-cia-4-121] In addition, 3% to 5% of patients die during the initial hospitalization for hip fracture, and approximately 20% to 40% die within 1 year.[@b12-cia-4-121],[@b17-cia-4-121]

Data indicate that older seniors with osteoporosis are frequently not treated with drug therapy.[@b18-cia-4-121]--[@b22-cia-4-121] A prospective cross-sectional study of nursing home residents (average age ∼80 years) with known osteoporosis or recent hip fracture revealed that 69% were receiving calcium and 63% vitamin D, but only 19% a bisphosphonate.[@b23-cia-4-121] Overall, only 36% were receiving any prescription medication or hip protector for osteoporosis. In a cross-sectional database analysis of newly admitted nursing facility residents (79.6% ≥75 years of age and 36.6% ≥85 years of age), only 9.1% were receiving an antiresorptive agent or calcium and vitamin D supplementation despite an expected high prevalence of osteoporosis in this population.[@b24-cia-4-121] Osteoporosis medication use was evaluated in 4430 patients who sustained a hip, wrist or humeral fracture and were admitted to a nursing home from 1995 to 2004.[@b19-cia-4-121] Mean age of the study population was 82.7 years. Only 11.5% of patients received any type of osteoporosis medication within 12 months of the fracture. The most common therapies prescribed were calcitonin (56%) followed by bisphosphonates (35.1%). Osteoporosis medication use within the previous 12 months was the best predictor of subsequent treatment (hazard ratio \[HR\] = 19.46; 95% confidence interval \[CI\], 16.02--23.63). A retrospective study, using a claims database, of postmenopausal women who sustained a distal radial fracture revealed that the rate of treatment for osteoporosis decreased significantly with increasing age (p \< 0.001), with 36% of patients age 55 to 59 years receiving treatment compared to 21.4% (age 75--79 years), 25.7% (age 80--84 years), 9.1% (age 85--89 years), 4.2% (age 90--94 years), and 4.7% (age ≥ 95 years).[@b18-cia-4-121]

The management of osteoporosis can be challenging in the older senior. Limited data regarding efficacy of drug therapy, multiple co-morbid conditions, increased risk for side effects from medications, and financial constraints have contributed to a discrepancy between the number of older seniors at risk for osteoporosis and the number being evaluated and treated. It is important for healthcare providers to be fully aware of the potential risks and benefits of diagnosing and treating osteoporosis in the older senior population.

Pathophysiology of fractures
============================

The two main factors that impact risk for a low-trauma fracture are skeletal fragility (eg, low bone density and poor bone quality) and falls. The risk for low bone density increases with age and significantly impacts bone strength. While difficult to measure, bone quality (alterations in bone geometry and microarchitecture) is also thought to be reduced with aging and contributes to compromised structural integrity of bone.[@b25-cia-4-121] In the older senior, falls become a greater factor in the risk for fractures.

It is estimated that 50% of seniors 85 years of age and older will fall at least once per year and half of those who fall will do so more than once.[@b26-cia-4-121] Approximately 5% of these falls result in a fracture.[@b26-cia-4-121] The risk for falls increases with advanced age.[@b27-cia-4-121],[@b28-cia-4-121] According to data from the National Center for Injury Prevention and Control, US seniors age 85 years of age and older had a much higher crude non-fatal and fatal fall rate compared to seniors age 65 to 69 years (non-fatal: 10.7 vs 2.5 per 100 persons and fatal: 143.7 vs 9.2 per 100,000 persons).[@b29-cia-4-121]

The more one falls, the greater their risk for fracture. Falls and fracture risk were evaluated in a large prospective cohort study of frail elderly in residential care facilities (mean age 85.7 years).[@b28-cia-4-121] Fall and fracture rates of 214 and 12.1 per 100 person years, respectively, were documented over the median 705 day follow-up period. Eighty-two percent of the fractures could be attributed to a fall. Subjects who fell frequently (\>3.08 falls per person-year) were 3 times more likely to suffer a fracture compared to subjects who did not fall (incident risk ratio = 3.35; 95% CI, 2.38--4.72). Fall rate was an independent predictor of fracture risk (p \< 0.001).

The risk for falls increases with advanced age due to a variety of factors. Impaired balance, gait and mobility; and poor vision, reduced muscle strength, and impaired cognition have all been found to be strong risk factors for falls.[@b26-cia-4-121],[@b30-cia-4-121] In addition, the use of multiple medications, especially psychoactive medications such as benzodiazepines, antidepressants, and antipsychotics, and certain co-morbid disease states such as stroke, Alzheimer's dementia and Parkinson's disease, have been strongly associated with falls and fractures.[@b26-cia-4-121],[@b30-cia-4-121]--[@b32-cia-4-121] The ability to adapt to falls also decreases with aging. Older seniors are more likely to sustain a hip fracture because they tend to fall backwards or sideways; leaving them unable to catch themselves or break their fall.[@b33-cia-4-121],[@b34-cia-4-121]

Vitamin D also plays an important role in bone strength and falls, with detrimental effects found in patients with vitamin D insufficiency and deficiency. It is estimated that 40% to 100% of US and European older men and women living in the community are insufficient or deficient in vitamin D.[@b35-cia-4-121] A recent study of long-term care residents (mean age 85 years) found that although 91% of patients were receiving vitamin D supplementation, 49.4% were vitamin D insufficient and 16% were found to be vitamin D deficient.[@b36-cia-4-121] In an older ambulatory population (mean age 78 years) where most of the patients were taking vitamin D supplements, 81% were found to be either insufficient or deficient in vitamin D.[@b37-cia-4-121]

Reduced 25-hydroxy vitamin D (25(OH) vit. D) concentrations lead to reduced calcium absorption, secondary hyperparathyroidism, an increase in bone resorption, and consequently fractures.[@b38-cia-4-121] A study of 119 community dwelling women (mean age 71 years) with a history of vertebral fracture found that mean bone turnover markers were significantly elevated in the vitamin D insufficient patients compared to those sufficient in vitamin D.[@b39-cia-4-121] In addition, bone mineral density (BMD) at the hip was significantly lower in the vitamin D insufficient patients than those sufficient in vitamin D (p \< 0.01). A positive correlation has also been observed elsewhere between serum 25(OH) vitamin D and BMD in older women, such that vitamin D deficiency is associated with lower femoral neck BMD.[@b38-cia-4-121]

Vitamin D is essential to maintain muscle function and strength, especially in the weight-bearing muscles of the lower body required for balance and walking. Vitamin D and its metabolites bind to skeletal muscles, affecting muscle cell growth and metabolism.[@b40-cia-4-121],[@b41-cia-4-121] A lack of vitamin D can cause muscle weakness and falls.[@b40-cia-4-121],[@b41-cia-4-121] Muscle weakness is typically in the proximal muscle groups and is characterized by a feeling of heaviness in the legs, tiring easily, and difficulty in climbing stairs and rising from a chair.[@b40-cia-4-121] Multiple studies have documented that vitamin D deficiency in older seniors is associated with reduced handgrip strength, inability to climb stairs, reduced walking distance, impaired leg extension power, and less outdoor activity.[@b40-cia-4-121] An Australian study of nursing home and hostel patients (median age 84 years) found that residents who fell had significantly lower 25(OH) vitamin D concentrations than other residents (p = 0.02).[@b41-cia-4-121]

Screening for osteoporosis
==========================

The prevalence of osteoporosis is high in the older senior; however, many do not realize they have the disease. According to NHANES data from 1988 to 1994, only 1.3% and 1.6% of men and 12.1% and 9.7% of women age 75 to 84 years and 85 years and older, respectively, reported they had osteoporosis.[@b42-cia-4-121] However when tested, 6.4% and 13.7% of men and 32.5% and 50.5% of women, respectively, had the disease. BMD testing using central dual-energy x-ray absorptionmetry (DXA) is the gold standard for identifying patients with osteoporosis. BMD testing is cost-effective in the older senior who is at highest risk for osteoporosis and has been show to significantly influence the decision to initiate drug therapy.[@b20-cia-4-121],[@b43-cia-4-121],[@b44-cia-4-121] In a report by the US Preventive Services Task Force, it was estimated that only 75 and 143 women between 75 and 79 years of age would need to be screened (and subsequently treated if necessary) to prevent one vertebral fracture and one hip fracture, respectively.[@b45-cia-4-121] This is in comparison to needing to screen 458 and 1856 women between the ages of 60 and 64 years. Universal bone density screening in women 65 years of age and older followed by treatment with alendronate was found to be more cost-effective with increasing age.[@b43-cia-4-121] The cost per quality adjusted life year (QALY) gained was approximately US\$43,000 for 65-year-old women, US\$5600 for 75-year-old women and cost saving for women 85 or 95 years of age or older. A similar analysis of the cost-effectiveness of densitometry followed by treatment in men revealed a cost per QALY gained of \<US\$50,000 in all men 65 years of age or older with a prior clinical vertebral fracture and men 80 years of age or older regardless of prior fracture.[@b44-cia-4-121] In the United Kingdom (UK), treatment with alendronate was cost effective (threshold value of £30,000 or €43,000/QALY gain) in women 60 years of age or older with osteoporosis (T-score −2.5 or below) and in women 50 years or older with a previous low-trauma fracture.[@b46-cia-4-121] Treatment with alendronate was cost saving in women 80 years or older with a prior low-trauma fracture. While alendronate was most cost effective (due to generic availability), most other therapies for osteoporosis were found to be cost effective in women aged 70 years and older with osteoporosis.

While guidelines recommend BMD testing in all women 65 years of age and older and men 70 years of age and older regardless of clinical risk factors, many older seniors do not receive a central DXA test.[@b5-cia-4-121],[@b20-cia-4-121],[@b47-cia-4-121],[@b48-cia-4-121] In the year 2000, the US Medicare system paid for 1.75 million bone density tests, which would account for only approximately 9% of US women over the age of 65 years.[@b49-cia-4-121] Similar results were seen in a study of bone mass measurement claims in US Medicare beneficiaries over the age of 65 years.[@b50-cia-4-121] From 1999 to 2005, only 30% of women and 4.4% of men underwent central DXA testing. According to a retrospective study of US Medicare administrative claims between 1999 and 2001, bone density screening of eligible women decreased with advancing age.[@b48-cia-4-121] Twenty-seven percent of eligible women between 66 and 70 years of age received bone density testing compared to only 16% of women age 81 to 85 years of age and 9.7% of women between 86 and 90 years of age. While testing rates were high in an academic geriatric practice, older seniors and those with lower functional status were less likely to be tested.[@b51-cia-4-121]

Central DXA BMD testing is under-utilized in the older senior. Logistical and cost issues associated with central DXA testing in institutionalized older seniors may be one of the main reasons. Calcaneal or forearm BMD measurements using portable quantitative ultrasound or peripheral DXA devices can be an alternative to assist with risk stratification in this population.[@b52-cia-4-121]--[@b55-cia-4-121] In addition, the 10-year probability for hip or major osteoporotic fracture can be calculated using selected clinical risk factors in the absence of BMD results with the World Health Organization (WHO) Fracture Risk Assessment Tool (FRAX). There are several international versions of this tool and four versions available specifically for Asians, Caucasians, Blacks, and Hispanics residing in the US. This tool is accessible at <http://www.shef.ac.uk/FRAX/>.[@b56-cia-4-121]

For the community-dwelling older senior, it is possible that the under-utilization of BMD testing is due to the misconception that it is too late to make an impact on osteoporosis in this population. It is important for healthcare providers to realize osteoporosis risk and adverse outcomes from fractures increase with age and that evidence consistently shows that those at highest risk for fracture are the ones that benefit most from interventions such as pharmacological therapy.[@b57-cia-4-121]

Diagnosis of osteoporosis
=========================

The diagnosis of osteoporosis is based on a low BMD T-score at the lumbar spine, total hip or femoral neck.[@b5-cia-4-121] A BMD T-score of −1.0 or higher (ie, a BMD within 1 standard deviation of that expected for a young, healthy adult of the same sex) is considered normal. A T-score between −1.0 and −2.5 is considered osteopenia, and a T-score of −2.5 or lower (ie, 2.5 or more standard deviations below the expected BMD) is considered osteoporosis. Patients with a T-score of −2.5 or lower and evidence of low-trauma fractures have severe osteoporosis. A diagnosis of osteoporosis may also be made clinically in at-risk individuals based on the presence of a low-trauma fracture.[@b5-cia-4-121]

Evaluation of the older senior with osteoporosis
================================================

All older seniors should undergo an investigation for secondary causes for osteoporosis as a part of the full evaluation of osteoporosis. Routine laboratory testing recommended for identifying the most common secondary causes for osteoporosis in older seniors is summarized in [Table 1](#t1-cia-4-121){ref-type="table"}. Vitamin D status is important to assess on a yearly basis in the older senior. There is, however, no universal agreement on what 25(OH) vitamin D concentrations constitute deficiency or insufficiency. Currently, most experts in the US agree that concentrations ≥75 nmol/L (≥30 ng/mL) define vitamin D sufficiency, concentrations between 50 and 72.5 nmol/L (20--29 ng/mL) define vitamin D insufficiency, and concentrations \<50 nmol/L (\<20 ng/ml) defines vitamin D deficiency.[@b35-cia-4-121]

All older seniors should be asked annually about the occurrence of falls, as patients who fall are at an increased risk for future falls. Any patient that reports a single fall should undergo a basic evaluation of gait/balance (eg, "Get Up and Go Test").[@b58-cia-4-121] Two or more falls or one fall with injury within the past year should prompt a thorough fall risk assessment.[@b59-cia-4-121] Items that should be included as part of a fall risk assessment are summarized in [Table 2](#t2-cia-4-121){ref-type="table"}.[@b58-cia-4-121]--[@b60-cia-4-121]

Treatment
=========

Bone-healthy lifestyle
----------------------

Exercise, fall prevention and smoking cessation in the older senior with osteoporosis should be encouraged whenever possible to help preserve BMD and reduce fracture risk ([Table 3](#t3-cia-4-121){ref-type="table"}).[@b58-cia-4-121]--[@b66-cia-4-121] Data show that aerobic, weight bearing and resistance exercise increases BMD of the spine and that walking alone increases BMD of both the hip and the spine in postmenopausal women.[@b62-cia-4-121] This type of exercise should be encouraged in older seniors too. However, a medical examination is recommended to make sure the patient is safe to exercise and to assess muscle strength, range of motion, level of physical activity, fitness, gait and identify balance problems.[@b61-cia-4-121] Exercise regimens should be tailored to individual patient abilities. Loading exercises that can be beneficial to the hip can result in compression fractures of the spine, so the intensity/resistance of exercise might need to be adjusted to BMD.[@b61-cia-4-121] An example daily exercise regimen recommended for seniors is: 1) a 5- to 10-minute warm-up session of walking, stretching, or calisthenics; 2) a 15- to 20-minute muscle conditioning program (eg, weight training); 3) 15 to 20 minutes of aerobics (eg, fast walking, jogging, stair stepping, biking, or vigorous dancing); and 4) a 5- to 10-minute cool-down session (eg, walking or stretching).[@b61-cia-4-121] Recently published guidelines from the American Heart Association recommend that all seniors (65 years and older) need moderate-intensity aerobic physical activity for at least 30 minutes on 5 days of each week, or vigorous-intensity aerobic activity for at least 20 minutes on 3 days of each week.[@b63-cia-4-121] The guideline also includes recommendations for 8 to 10 exercises using the major muscle groups on 2 or more days per week, at least 10 minutes of activities to maintain or increase flexibility on at least 2 days of each week, and exercises to maintain or improve balance in those with substantial risk of falls.[@b63-cia-4-121] Although not necessarily targeted for the "older senior," these recommendations come from data that regular physical activity reduces risk of many diseases, plays a therapeutic role in diseases such as osteoporosis, reduces risk of falls and injuries from falls, and reduces functional limitations. Thus, exercise and muscle strengthening should still be encouraged as much as possible in the older senior.

Other methods of preventing falls include home environment modifications (eg, removing loose rugs or extension cords, repairing rickety stairs, adding grab bars in the bathroom, increasing lighting), assessing vision and treating any remedial visual abnormalities, assessing need for ambulation-assistive devices (eg, canes and walkers), treatment of cardiovascular causes of falls (eg, orthostatic hypotension, arrhythmias) and eliminating medications that can increase risk of falls (eg, antipsychotic agents, benzodiazepines, antidepressants, antihypertensives, diuretics).[@b58-cia-4-121]

Smoking cessation is also recommended for the older senior with osteoporosis. One year of smoking cessation has been shown to significantly increase BMD in the femoral trochanter (p = 0.02) and total hip (p = 0.03) relative to continuation of smoking in postmenopausal women.[@b67-cia-4-121] Moreover, smoking cessation has been found to reduce the risk of hip fracture compared to continuation of smoking in non-elderly women, although the benefit was not evident until 10 years after cessation.[@b68-cia-4-121] Despite a lack of data in older seniors and that the benefits of smoking cessation for osteoporosis may be delayed, the other health benefits of smoking cessation (eg, vascular, pulmonary) make it important for all older seniors.

Hip protectors
--------------

External hip protectors are specialized undergarments designed to pad the area surrounding the hip decreasing the force of impact from a sideways fall. Individual studies evaluating the effectiveness of these products have demonstrated conflicting results.[@b69-cia-4-121] Poor compliance is the main drawback with these devices, as patients tend to find them uncomfortable and cosmetically unappealing. A recent meta-analysis of randomized controlled trials demonstrated no benefit from hip protectors in community-dwelling seniors.[@b69-cia-4-121] In addition, there was no difference in hip fracture rates in a large, multicenter, randomized controlled trial of nursing home residents.[@b70-cia-4-121] These data indicate that hip protectors are ineffective and should not be recommended alone for the prevention of hip fractures.

Calcium and vitamin D
---------------------

All patients with osteoporosis, regardless of age, should receive adequate calcium and vitamin D ([Table 3](#t3-cia-4-121){ref-type="table"}).[@b5-cia-4-121],[@b35-cia-4-121],[@b71-cia-4-121],[@b72-cia-4-121] Diet alone is usually not adequate to maintain recommended intakes of calcium and vitamin D, and supplementation is almost always necessary. Many studies have evaluated the effects of calcium and vitamin D on BMD and fractures and vitamin D on falls in older adults. A meta-analysis of calcium and calcium/vitamin D supplementation found that the supplements significantly reduced fracture risk by 12% (p = 0.004) and reduced bone loss by 0.54% (p \< 0.0001) at the hip and 1.19% (p \< 0.0001) in the spine.[@b73-cia-4-121] In a subgroup analysis based on age, fracture risk reduction was significantly greater in those aged 70 to 79 years (relative risk \[RR\] 0.89, 95% CI 0.82--0.96) and those aged ≥80 years (RR 0.76, 95% CI 0.67--0.87) compared to those age 50 to 69 years (RR 0.97, 95% CI 0.92--1.02), p = 0.003.[@b73-cia-4-121] In the same meta-analysis, calcium doses of ≥1200 mg per day and vitamin D doses of ≥800 international units (IU) per day were found to be statistically better at preventing fractures than lower doses (p = 0.006 and p = 0.03, respectively).[@b73-cia-4-121]

Vitamin D monotherapy in doses between 700 to 800 IU per day has also been shown in a meta-analysis to reduce the risk of hip and any non-vertebral fractures in ambulatory and institutionalized seniors.[@b74-cia-4-121] A Cochrane review published around the same time found that vitamin D alone showed no statistically significant effect on hip, vertebral or any new fracture.[@b75-cia-4-121] However, it does not appear that the authors evaluated the data based on the dose of vitamin D. An even more recent meta-analysis concluded that oral vitamin D appears to reduce the risk of hip fractures only when it is combined with calcium supplementation.[@b76-cia-4-121] Studies regarding the use of vitamin D supplements to prevent fractures are conflicting, likely because patient populations may have different baseline 25(OH) vitamin D concentrations, interventions may utilize different forms of vitamin D (eg, ergocalciferol vs cholecalciferol), and doses may be different (eg, \<800 IU per day vs ≥800 IU per day). Unfortunately, none of the studies described above performed analyses to evaluate effects based on subject age.

The effects of vitamin D monotherapy on falls was evaluated in a meta-analysis that found that vitamin D reduced the odds ratio of falling by 22% (corrected odds ratio 0.78, 95% CI 0.64--0.092) compared with patients (mean age ranged from 70 to 85 years) receiving calcium or placebo.[@b64-cia-4-121] Since the meta-analysis of vitamin D and falls was published, multiple other studies evaluating effects of vitamin D supplementation on falls have been published, most of which are positive.[@b65-cia-4-121] A prospective, randomized, multi-dose study of nursing home residents (mean age 89 years) found that those taking 800 IU per day of vitamin D2 supplementation had a 72% lower adjusted-incidence rate of falls than those taking placebo (RR 0.28, 95% CI 0.11--0.75) over 5 months.[@b77-cia-4-121] Patients taking 200 IU per day, 400 IU per day and 600 IU per day of vitamin D had similar fall rates to those taking placebo. A 2005 study of 625 independent and institutionalized older seniors (mean age 83 years) found that ergocalciferol (10,000 IU weekly then 1000 IU daily) and calcium carbonate 600 mg daily demonstrated an incident rate ratio of falling of 0.73 (95% CI 0.57--0.95) compared to placebo.[@b66-cia-4-121] This translates to 8 patients treated with vitamin D over 1 year to prevent one fall from occurring.[@b66-cia-4-121] Two negative studies in older seniors (mean ages 85 and 84 years, respectively) utilized bolus dosing of ergocalciferol 100,000 units (every 3 months and every 4 months, respectively), which may explain their finding of lack of efficacy to prevent falls and fractures.[@b78-cia-4-121],[@b79-cia-4-121] Evidence suggests that large infrequent doses of ergocalciferol may provide only short-term benefits, as compared to cholecalciferol.[@b65-cia-4-121]

Although data regarding vitamin D monotherapy might be conflicting regarding fracture and fall reduction, it is apparent that combination calcium and vitamin D supplementation is beneficial for older seniors. In addition, supplementation is inexpensive and well-tolerated. Vitamin D3 (cholecalciferol) is the preferred formulation for vitamin D supplementation. The total daily vitamin D dose can be given via a multi-vitamin, calcium plus vitamin D, and/or vitamin D alone. Often a combination of the products containing vitamin D is necessary to achieve adequate 25(OH) vitamin D concentrations.

Calcium is typically supplemented utilizing either calcium carbonate or calcium citrate. The calcium citrate form may be advantageous for older seniors, since calcium citrate absorption does not rely on gastric acid like calcium carbonate, and older seniors may suffer from achlorhydria. Moreover, patients taking proton pump inhibitors (PPIs) may benefit more from supplementation with calcium citrate. One small study found that calcium carbonate absorption was inhibited by co-administration with omeprazole.[@b71-cia-4-121] Since many older seniors may also take a PPI, it may be prudent to recommend supplementation with calcium citrate in those patients. In addition, it may be appropriate to assess the need of the PPI, as long-term treatment with PPIs has been associated with increased risk of hip fracture.[@b72-cia-4-121] It is not known if the increased risk of hip fracture is due to the effect of PPIs on calcium absorption.

Calcium and vitamin D supplementation in the older senior is well tolerated, other than possible constipation associated with the calcium component. Hypercalcemia and hyperphosphatemia rarely occur. Vitamin D toxicity is extremely rare and usually only occurs with long-term administration of extremely high doses, such as 50,000 IU per day or more.[@b35-cia-4-121] Currently, the tolerable upper intake level of vitamin D is set at 2000 units per day, although with proper monitoring older seniors may benefit from higher doses. Doses of vitamin D should be titrated to achieve a serum 25(OH) vitamin D concentration of 75 to 150 nmol/L (30--60 ng/mL) to fully maximize calcium absorption and benefits on BMD and muscles.[@b35-cia-4-121]

Drug therapy
------------

The 2008 National Osteoporosis Foundation (NOF) Clinician's Guide recommends treatment of postmenopausal women and men 50 years of age or older with (1) a hip or vertebral fracture, (2) a femoral neck, total hip, or spine T-score of −2.5 or less measured by central DXA, or (3) a T-score between −1.0 and −2.5 measured by central DXA (ie, osteopenia) and other prior fractures, a secondary cause associated with a high risk of fractures, a 10-year hip fracture probability of 3% or higher, or a 10-year probability of major osteoporosis-related fracture (vertebral, hip, forearm, or humerus fracture) of 20% or higher.[@b5-cia-4-121] These probabilities are calculated using the WHO FRAX tool.[@b56-cia-4-121] According to this guideline all older seniors with the diagnosis of osteoporosis would warrant drug therapy. In addition, using the US FRAX to calculate the 10-year probability for fracture, the majority of Caucasian women 80 years of age or older would meet criteria for treatment at a T-score of −1.7 or less even in the absence of additional clinical risk factors.

The NOF Clinicians Guide is more aggressive in recommending drug therapy in the older senior compared to other Guidelines. The National Osteoporosis Guideline Group from the UK published in 2008 recommendations for the prevention and treatment of osteoporosis in postmenopausal women and men age ≥ 50 years.[@b80-cia-4-121] They recommend age-based treatment thresholds using the 10-year probability of a major osteoporotic fracture from the UK specific FRAX tool. According to this guideline, the intervention threshold for an 80-year-old man with or without previous fracture and an 80-year-old postmenopausal woman with no previous fracture would be a 10-year probability of major osteoporotic fracture of at least 30%. An updated list of National and Regional Osteoporosis Guidelines can be found at the International Osteoporosis website: <http://www.iofbonehealth.org/health-professionals/national-regional-guidelines/evidence-based-guidelines.html>.

Drug therapy for the management of osteoporosis in the older senior is summarized in [Table 4](#t4-cia-4-121){ref-type="table"}.[@b81-cia-4-121]--[@b105-cia-4-121] The majority of pharmacological interventions available are considered antiresorptive (bisphosphonates, calcitonin, raloxifene, and hormone replacement therapy). Only parathyroid hormone is considered truly anabolic or bone building. The mechanism of action of strontium ranelate is not completely understood, but is thought to reduce bone resorption while maintaining bone formation. All these interventions have been shown to reduce the risk of vertebral fracture when given with calcium and vitamin D supplements. Some have been shown to also reduce the risk of non-vertebral fractures and specifically hip fractures.[@b81-cia-4-121],[@b88-cia-4-121],[@b89-cia-4-121],[@b93-cia-4-121],[@b99-cia-4-121] Intravenous zoledronic acid may reduce mortality in patients with a previous hip fracture.[@b92-cia-4-121]

When deciding whether or not to institute drug therapy for the management of osteoporosis in the older senior, several factors need to be taken into consideration. First it is important to determine if there is evidence to support a benefit from osteoporosis therapy in the older senior. In 2003, the average additional life span for a 75-year-old in the US was 11.8 years and for an 85-year-old was 6.8 years.[@b106-cia-4-121] Data for most osteoporosis therapies show significant decreases in vertebral fracture rates as early as 6 months to 1 year.[@b93-cia-4-121],[@b107-cia-4-121],[@b108-cia-4-121] Unless there is a comorbid condition that is expected to significantly reduce life expectancy, many older seniors will live long enough to potentially derive a benefit from osteoporosis drug therapy.

Similar to other disease states, efficacy data are lacking in the older senior population, with the majority of information coming from post hoc subgroup analyses. In an analysis of data from the Fracture Intervention Trial with alendronate, the relative risk reductions for clinical fractures at the hip, spine and wrist with alendronate therapy were found to be constant across all age groups up to the age of 85 years.[@b109-cia-4-121] The absolute risk reduction (ARR) between alendronate and placebo increased with increasing age. For example, the ARR for hip fracture was 11 per 10,000 person-years for women 55 to 64 years of age and 53 per 10,000 person-years for women 75 to 85 years of age. Comparable results were seen in a post hoc analysis by Ensrud and colleagues.[@b57-cia-4-121] Statistically significant relative risk reductions in new vertebral fractures were seen with alendronate therapy compared to placebo both in women \<75 years of age (relative risk \[RR\] = 0.49; 95% CI, 0.35--0.68) and 75 to 82 years of age (RR = 0.62; 95% CI, 0.41--0.94).

Pivotal studies of risedronate compared to placebo did not exclude subjects based on age. A pooled analysis of data from these studies demonstrated a statistically significant 44% relative risk reduction for new vertebral fractures at 3 years with risedronate therapy in women between 80 and 100 years of age (HR = 0.56, 95% CI = 0.39--0.81, p = 0.03).[@b110-cia-4-121] There was no significant difference in non-vertebral fracture risk between risedronate and placebo in the population. Risedronate is the only oral therapy to be evaluated in a large, prospective clinical trial with hip fracture reduction as the primary endpoint.[@b88-cia-4-121] Postmenopausal women were enrolled into two arms. The osteoporosis arm included women aged 70 to 79 years with documented osteoporosis. The risk factor arm included women 80 years and older (mean age 83 years) with either one non-skeletal risk factor for hip fracture or osteoporosis. The majority of the subjects in this arm did not have central DXA results and were enrolled based on risk factors for fall. Overall, risedronate reduced the risk of hip fractures by 30% (RR = 0.70, 95% CI, 0.6--0.69). However, when the two groups were evaluated independently, the incidence of hip fracture was not significantly reduced in the risk factor arm (RR = 0.8, 95% CI, 0.6--1.2).

The HORIZON-Pivotal Fracture Trial (PFT) compared zoledronic acid infused intravenously once-yearly to placebo on vertebral and hip fracture risk in postmenopausal women with osteoporosis.[@b93-cia-4-121] A post hoc analysis of results stratified according to age groups (\<70 years, 70--74 years and ≥75 years) demonstrated that new vertebral and non-vertebral fractures were significantly reduced in all age groups.[@b111-cia-4-121] In this analysis, the relative risk for new vertebral fractures were reduced by 60% (p \< 0.001) in those women ≥ 75 years of age compared to 80% (p \< 0.001) in those \<70 years of age. Hip fracture risk was only significantly reduced in the \<70 years age group (RR = 0.30; p \< 0.05). The HORIZON-Recurrent Fracture Trial (RFT) randomized men and women with a prior hip fracture to receive once yearly intravenous infusions of zoledronic acid.[@b92-cia-4-121] Over 50% of the subjects enrolled were 75 years of age or older. A statistically significant 35% reduction in any clinical fracture (p = 0.001) and 28% reduction in all cause mortality (p = 0.01) was demonstrated in the treatment group compared to placebo. The reduction in hip fracture risk did not reach statistical significance.

An analysis of the Fracture Prevention Trial with teriparatide demonstrated a similar benefit with therapy compared to placebo in younger and older women.[@b112-cia-4-121],[@b113-cia-4-121] For women younger than 75 years and those aged 75 years and older, teriparatide therapy resulted in an ARR for new vertebral fracture of 9.2% (RR = 0.35, p \< 0.01) and 9.9% (RR = 0.35, p \< 0.05), respectively compared to placebo.[@b112-cia-4-121] Non-vertebral fracture risk was not significantly reduced in the ≥75 years of age group with teriparatide therapy (RR = 0.75, p = 0.66). However, the treatment-by-age interaction (p = 0.42) indicated that the effect of teriparatide on non-vertebral fractures was not significantly different between those \<75 or those ≥75 years of age.

A pre-planned pooled analysis of studies with oral strontium ranelate compared to placebo evaluated efficacy in women with osteoporosis who were between the age of 80 and 100 years (mean age 84 years).[@b114-cia-4-121] Over 3 years, the relative risk for vertebral and non-vertebral fractures was significantly reduced by 32% (p = 0.013) and 31% (p \< 0.011), respectively in the strontium-treated patients. Hip fracture risk reduction did not reach statistical significance (32%, p = 0.112).

The Multiple Outcomes of Raloxifene Evaluation (MORE) study enrolled postmenopausal women age 31 to 80 years.[@b94-cia-4-121] The mean age of the study subjects was 67 years. Subgroup analyses based on age are not available.

The Women's Health Initiative evaluated the effects of estrogen with or without progestin on several chronic disease states including fractures in healthy postmenopausal women age 50 to 79 years.[@b104-cia-4-121],[@b105-cia-4-121] Reductions in clinical vertebral and hip fractures were seen, and the results did not differ with age stratification. Hormone replacement therapy is only indicated in the US for the prevention of osteoporosis and should not be used solely for this purpose.[@b5-cia-4-121]

Subgroup analyses, while not ideal, have consistently demonstrated a significant reduction in vertebral fracture risk with drug therapy across all age groups. The inconsistent benefit seen in non-vertebral fracture risk in older patients may be due to the fact that improvement in bone strength is overshadowed by increasing fall risk in this population.

Only one study has been prospectively designed to evaluate the efficacy of therapy in the older patient (mean age 78.5 years; range 65--91 years) residing in a long-term care facility. In this study, alendronate 10 mg po once daily for 2 years significantly increased BMD at the hip and spine compared to placebo, with no difference in adverse events between groups.[@b115-cia-4-121] Fracture risk was not evaluated in this study.

Intranasal calcitonin is frequently prescribed in the older senior population, possibly due to its benign side effect profile and ease of administration.[@b22-cia-4-121] Calcitonin has not been shown to improve hip BMD or reduce hip fracture risk.[@b97-cia-4-121] Based on vertebral fracture efficacy, it is considered a third line therapy option for osteoporosis management. Efficacy data are not available for the older senior; however in the Prevent Recurrence of Osteoporotic Fractures study, 21% to 25% of the women enrolled were ≥75 years of age.[@b97-cia-4-121]

Some evidence suggests that calcitonin may have an analgesic effect. Small studies have demonstrated a short-term benefit from calcitonin therapy on pain in senior men and women who have suffered an acute vertebral compression fracture.[@b98-cia-4-121],[@b116-cia-4-121],[@b117-cia-4-121] The short-term (∼4 weeks) administration of intranasal calcitonin for pain relief should not preclude the use of more efficacious therapies, such as bisphosphonates, for the treatment of osteoporosis.

Limited studies have evaluated the benefit of pharmacologic treatment in men.[@b118-cia-4-121]--[@b123-cia-4-121] The mean age of the subjects in the majority of the studies was \<65 years.[@b118-cia-4-121],[@b121-cia-4-121]--[@b123-cia-4-121] While small in size, these studies did demonstrate improvements in BMD similar to studies in postmenopausal women and two studies showed significant reductions in vertebral fracture risk.[@b121-cia-4-121],[@b123-cia-4-121] Two studies have evaluated the effect of risedronate on hip fracture risk in older men. In 280 men post stroke (mean age 76 years), 2.5 mg risedronate daily significantly reduced hip fracture risk by 81% (RR = 0.19, 95% CI, 0.04--0.89) compared to placebo.[@b119-cia-4-121] In 223 men with Parkinson's Disease (mean age = 71.3 years; range 65 to 85), 2.5 mg risedronate daily did not significantly reduce hip fracture risk compared to placebo (RR = 0.33; 95% CI, 0.09--1.20).[@b120-cia-4-121] More studies are needed to fully understand the benefits and risks of osteoporosis therapy in older men.

In addition to efficacy, one needs to consider the risks of pharmacological treatment in the older senior. Administration of oral bisphosphonates, which are considered first line therapy for osteoporosis, can be challenging in the older senior. To ensure adequate absorption, patients cannot eat, drink (other than plain water), or consume any medications for 30 to 60 minutes after taking a bisphosphonate. To reduce the risk for esophageal side effects, patients need to take the medication with at least 180 to 240 mL (6--8 ounces) of plain water and be able to sit upright for at least 30 to 60 minutes after taking. These instructions can be especially difficult for institutionalized or cognitively impaired seniors. A significant number of seniors have gastrointestinal complaints, which are the most common side effects of oral bisphosphonates. While clinical trial data do not indicate an increased risk for side effect in older subjects compared to younger subjects, real-world experience indicates an increased risk of these effects if the medication is not taken appropriately.[@b110-cia-4-121],[@b124-cia-4-121] A recent letter to the editor summarizes US Food and Drug Administration (FDA) reports of esophageal cancer diagnoses in patient taking oral bisphosphonates.[@b125-cia-4-121] It is possible that inappropriate administration contributed to some of these cases. The older senior is frequently on multiple oral medications. The addition of an oral osteoporosis medication (including calcium and vitamin D) can add complexity to an already challenging medication regimen leading to potential adherence problems. Adherence at one year is poor with these agents and studies have demonstrated a reduced fracture benefit in patients with poor adherence.[@b126-cia-4-121]--[@b128-cia-4-121]

Intravenous bisphosphonates are an option in the older senior who cannot tolerate or may have difficulty adhering to oral bisphosphonate therapy. Quarterly intravenous injections of ibandronate or a once yearly infusion of zoledronic acid may significantly improve adherence in this population. The most common side effects are short-term flu-like symptoms (eg, myalgias, arthralgias, pyrexia).[@b91-cia-4-121]--[@b93-cia-4-121] In the HORIZON-PFT, an increased incidence of serious atrial fibrillation was observed in the zoledronic acid group (1.3%) compared to placebo (0.5%), p \< 0.001.[@b92-cia-4-121],[@b93-cia-4-121] No plausible biological explanation could be found. In addition, the rates of atrial fibrillation were similar between the zoledronic acid and placebo groups in the HORIZON-RFT.[@b92-cia-4-121] The risk for atrial fibrillation increases with age. A possible increased risk for atrial fibrillation with bisphosphonates therapy could be a concern in the older senior. Due to conflicting evidence on the link between atrial fibrillation and the use of bisphosphonates,[@b129-cia-4-121]--[@b131-cia-4-121] the FDA conducted a review of all safety data and concluded that there was "no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation. Increasing dose or duration of bisphosphonate therapy was also not associated with an increased rate of atrial fibrillation." The FDA is continuing to monitor postmarket reports of atrial fibrillation in patients who have taken bisphosphonates.

Raloxifene, an estrogen agonist-antagonist, is considered a second line option for the management of osteoporosis in older seniors and is FDA-approved in the US for use in post-menopausal women at high risk for invasive breast cancer.[@b132-cia-4-121] It is administered orally on a daily basis, which may result in lower adherence compared with less frequently administered bisphosphonates. Side effects are also a concern with this therapy as raloxifene has been shown to increase venous thromboembolism risk by 3-fold and fatal stroke risk (1.2% raloxifene vs 0.8% placebo, p = 0.0499).[@b95-cia-4-121],[@b96-cia-4-121]

Teriparatide and parathyroid hormone 1--84 are administered by subcutaneous injection once daily. They are an option for patients that are at high risk for fracture or who cannot tolerate or fail other therapies. While side effects are limited (first dose dizziness and transient hypercalcemia), daily administration of these therapies in the older senior can be challenging.

Special considerations
----------------------

Kidney function or glomerular filtration rate (GFR) declines with aging. Many older seniors with osteoporosis have estimated GFRs of \<60 mL/min and some \<30 mL/min without any evidence for kidney damage.[@b133-cia-4-121],[@b134-cia-4-121] According to package labeling, oral and iv bisphosphonates are not recommended for patients with a creatinine clearance (CrCl) \< 30 or 35 mL/min. Approximately 50% of the absorbed dose of a bisphosphonate is excreted unchanged by the kidney; therefore, reductions in kidney function have the potential to result in accumulation of the bisphosphonate. It is important to know if bisphosphonates are efficacious and safe to use in the older senior with reduced kidney function.

The influence of baseline kidney function on the safety and efficacy of once daily risedronate was evaluated in a retrospective analysis of data from 9 randomized, double-blind, placebo-controlled trials.[@b135-cia-4-121] CrCl was estimated using the Cockcroft and Gault method. There was no difference in side effect rates or the risk for vertebral fractures among patients with mild (CrCl 50--79 mL/min), moderate (CrCl 30--49 mL/min) or severe kidney impairment (CrCl 15--30 mL/min). The mean age of the patients in the severe kidney impairment group was 83 years compared to 71 years in the mild group.

In a study using data with teriparatide, postmenopausal women with impaired kidney function (CrCl 30--79 mL/min) had comparable rates of adverse events, increases in BMD, and decreases in vertebral and non-vertebral fracture risk as postmenopausal women with normal kidney function (CrCl ≥ 80 mL/min).[@b136-cia-4-121] Alendronate also demonstrated similar efficacy in postmenopaual women with reduced kidney function (CrCl \< 45 mL/min) as women without reduced kidney function.[@b137-cia-4-121]

The efficacy and safety of raloxifene by degree of kidney impairment was examined using data from the MORE trial.^138^ This post hoc analysis demonstrated raloxifene was effective and well tolerated in patients with mild to moderate kidney impairment (mean CrCl 40 mL/min). Package labeling indicates raloxifene should be used with caution in patients with moderate or severe renal impairment since safety and efficacy have not been established. Based on the results of these studies, teriparatide may be an option for older seniors with moderate kidney impairment (CrCl 30--49 mL/min) and oral bisphosphonates, specifically risedronate, in older seniors with severe age-related kidney impairment (CrCl as low as 15 mL/min). There are no data regarding safety and efficacy of intravenous bisphosphonates in patients with severe kidney impairment, but those with a CrCl ≥ 30 mL/min were included in the HORIZON studies. Renal safety of zoledronic acid was evaluated in the HORIZON studies. A significant increase in serum creatinine of more than 0.5 mg/dL occurred at 9 to 11 days after infusion in 1.2% of the treatment group compared to 0.4% of the placebo group (p \< 0.001) in HORIZON-PFT.[@b93-cia-4-121] There was no difference between groups in serum creatinine or CrCl at the end of the study. In addition, no significant increase in serum creatinine was noted in the HORIZON-RFT.[@b92-cia-4-121]

Conclusion
==========

The older senior is at high risk for osteoporosis. Bone mineral density testing with central DXA is essential and cost-effective in this population. Based on subgroup analyses of large osteoporosis trials in postmenopausal women, current osteoporosis therapies appear safe and efficacious in the older senior and most will live long enough to derive a benefit from these therapies. The risk for vitamin D insufficiency and deficiency is high and should be treated appropriately. It is important to remember that falls play a very important role in the risk for osteoporosis fractures, especially in the older senior. Strategies to reduce fall risk in this population will be just as important as pharmacological therapy. Further studies are needed in older seniors, especially men, to better understand the risks and benefits of pharmacologic therapy for the management of osteoporosis.
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###### 

Suggested routine laboratory tests for the evaluation of secondary causes of osteoporosis in the older senior

  **Laboratory test**                               **Secondary cause**
  ------------------------------------------------- ------------------------------------------------------
  Serum creatinine and blood urea nitrogen          Chronic kidney disease
  Serum alkaline phosphatase                        Paget's disease; osteomalacia
  Serum thyroid-stimulating hormone concentration   Hyperthyroidism or over-supplementation of thyroxine
  Serum calcium and phosphorous concentrations      Vitamin D deficiency; malabsorption
  24-hour urinary calcium                           Excessive urinary excretion of calcium
  Total serum testosterone (men)                    Hypogonadism
  25-hydroxy vitamin D                              Vitamin D insufficiency/deficiency
  Intact serum parathyroid hormone                  Primary or secondary hyperparathyroidism
  Serum protein electrophoresis                     Multiple myeloma
  Complete blood count                              Leukemia
  Liver function tests                              Chronic liver disease

###### 

Fall risk assessment in the older senior[@b58-cia-4-121]--[@b60-cia-4-121]

  **Fall risk assessment[a](#tfn1-cia-4-121){ref-type="table-fn"}**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Basic fall history (eg, number and circumstances surrounding falls)
  Medication review: eliminate unnecessary or inappropriate psychoactive medications including antipsychotics, anxiolytics, hypnotics, antidepressants, muscle relaxants, anticholinergics and narcotics, and medications such as diuretics or certain antihypertensives known to cause postural hypotension
  Document alcohol consumption
  Document acute or chronic medical conditions
  Document orthostatic vitals (blood pressure and pulse)
  Visual acuity testing
  Basic gait, balance, and strength evaluation (eg, basic neurological exam to evaluate muscle strength, cerebellar function and peripheral sensory function; "Get Up and Go Test"[b](#tfn2-cia-4-121){ref-type="table-fn"})
  Cognitive status (eg, Mini-Mental State Exam)
  Evaluation of home and personal safety

^a^Recommended assessment for patients with two or more falls or one fall with injury within the past year.

^b^"Get Up and Go Test": patients are instructed to stand from a seated position without using their hands, walk 10 feet, turn around, return to the chair and sit down. Patients that take longer than 30 seconds are at a higher risk for falls.

###### 

Recommendations for a bone-healthy lifestyle in the older senior

  **Intervention**                                                                       **Recommendations**                                                                                                                                                                                                                                                                                           **Comments**
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exercise[@b61-cia-4-121]--[@b63-cia-4-121]                                             Moderate-intensity aerobic physical activity for ≥30 minutes for 5 days/week.8--10 exercises using the major muscle groups for ≥2 days/week≥ 10 minutes of activities to maintain or increase flexibility for ≥2 days/weekExercises to maintain/improve balance in older seniors with substantial fall risk   A physical examination should be performed prior to starting an exercise regimen. The exercise regimen should be tailored to each individual patient.
  Fall prevention[@b58-cia-4-121]--[@b60-cia-4-121],[@b64-cia-4-121]--[@b66-cia-4-121]   Physical activity (as above)Home environment modificationsVision assessmentUse of ambulation-assistive devicesTreatment of cardiovascular causes of fallsEliminating unnecessary medicationsVitamin D supplementation                                                                                         
  Calcium[@b5-cia-4-121],[@b71-cia-4-121],[@b72-cia-4-121]                               1200--1500 mg calcium divided two to three times daily                                                                                                                                                                                                                                                        Older seniors taking proton pump inhibitors may benefit from calcium citrate. Patients should be counseled regarding possible side effect of constipation.
  Vitamin D[@b5-cia-4-121],[@b35-cia-4-121]                                              To avoid deficiency 800--1000 IU vitamin D3 daily OR50,000 IU vitamin D2 every 2--4 weeks                                                                                                                                                                                                                     
  To treat deficiency 50,000 IU vitamin D2 every week for 8--16 weeks                                                                                                                                                                                                                                                                                                                                  

**Abbreviation:** IU, international units.

###### 

Pharmacologic therapy for osteoporosis in the older senior

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug**                                                                              **Dosing**                                                                    **Efficacy[a](#tfn4-cia-4-121){ref-type="table-fn"} antiresorptive agents (relative risk reduction)**   **Safety**                                                                                                                                                                                                                                            **Comments**
  ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  **Oral bisphosphonates**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Alendronate[@b81-cia-4-121]--[@b86-cia-4-121]                                         10 mg po once daily\                                                          VF: 47%\                                                                                                GI side effects (eg, nausea, dyspepsia, esophagitis, GI ulceration); muscle pain; small risk for osteonecrosis of the jaw; Not recommended if CrCl \< 30--35 ml/min (may be able to use risedronate in patients with CrCl between 15 and 30 ml/min)   Available in liquid form and in combination with cholecalciferol 2800 or 5600 units; Approved for use in men; Generic
                                                                                        70 mg po once weekly                                                          HF: 51%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                      NVF: 20% (NS)                                                                                                                                                                                                                                                                                                                                                 

  Risedronate[@b87-cia-4-121]--[@b89-cia-4-121]                                         5 mg po once daily\                                                           VF: 41%--49%\                                                                                                                                                                                                                                                                                                                                                 Approved for use in men
                                                                                        35 mg po once weekly\                                                         HF: 30%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                        150 mg po once monthly                                                        NVF: 40%                                                                                                                                                                                                                                                                                                                                                      

  Ibandronate[@b90-cia-4-121]                                                           2.5 mg po once daily\                                                         VF: 52%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                        150 mg po once monthly                                                        HF: NR\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: NS                                                                                                                                                                                                                                                                                                                                                       

  **Intravenous bisphosphonates**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Ibandronate[@b82-cia-4-121]--[@b84-cia-4-121],[@b91-cia-4-121]                        3 mg iv injection over\                                                       Antifracture efficacy demonstrated with oral ibandronate                                                Short-term flu-like symptoms (pyrexia, myalgias, arthralgias); muscle pain; small risk for osteonecrosis of the jaw; possible small increase in serum creatinine; Not recommended if CrCl \< 30--35 mL/min                                            
                                                                                        3--5 seconds every 3 months                                                                                                                                                                                                                                                                                                                                                                                                                 

  Zoledronic acid[@b82-cia-4-121]--[@b84-cia-4-121],[@b92-cia-4-121],[@b93-cia-4-121]   5 mg iv infusion over\                                                        VF: 70%\                                                                                                                                                                                                                                                                                                                                                      Approved for use in men
                                                                                        15 minutes once yearly                                                        HF: 41%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                      NVF: 25%--27%\                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                      All cause mortality: 28%                                                                                                                                                                                                                                                                                                                                      

  **Other**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Raloxifene[@b94-cia-4-121]--[@b96-cia-4-121]                                          60 mg po once daily                                                           VF: 30%\                                                                                                Increased risk for VTE and fatal stroke                                                                                                                                                                                                               Approved to reduce the risk for invasive breast cancer
                                                                                                                                                                      HF: NS\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: 10% (NS)                                                                                                                                                                                                                                                                                                                                                 

  Calcitonin[@b97-cia-4-121],[@b98-cia-4-121]                                           200 IU (one puff) intranasally once daily alternating nostrils                VF: 33%\                                                                                                Nasal effects (eg, irritation, congestion, discharge, sneezing)                                                                                                                                                                                       Possible analgesic effects
                                                                                                                                                                      HF: NS\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: NS                                                                                                                                                                                                                                                                                                                                                       

  Hormone replacement therapy[@b104-cia-4-121],[@b105-cia-4-121]                        CEE 0.625 mg orally once daily with or without MPA 2.5 mg orally once daily   VF: 35%--38%\                                                                                           Increased risk for cardiovascular disease, breast cancer, stroke, dementia and VTE                                                                                                                                                                    Only FDA indicated for the prevention of osteoporosis
                                                                                                                                                                      HF: 33%--39%\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                      WF: 29%                                                                                                                                                                                                                                                                                                                                                       

  **Anabolic agents**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Teriparatide (parathyroid hormone 1--34)[@b99-cia-4-121]                              20 mcg sc injection once daily                                                VF: 65%\                                                                                                Mild hypercalcemia, nausea, headache, dizziness, leg cramps; Contraindicated in patients with a history of prior radiation therapy to the skeleton and severe kidney dysfunction                                                                      Approved for use in men; Use approved for only 24 months
                                                                                                                                                                      HF: NS\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: 54%                                                                                                                                                                                                                                                                                                                                                      

  Parathyroid hormone (1--84)[@b100-cia-4-121]                                          100 mcg sc injection once daily                                               VF: 61%\                                                                                                Hypercalcemia, hypercalciuria, nausea, headache, dizziness, muscle cramps; Contraindicated in patients with a history of prior radiation therapy to the skeleton and severe kidney dysfunction                                                        Approved outside the US; Use approved for only 24 months; need to monitor serum or urinary calcium at 1, 3 and 6 months
                                                                                                                                                                      HF: NS\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: NS                                                                                                                                                                                                                                                                                                                                                       

  **Antiresportive/anabolic agents**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Strontium[@b101-cia-4-121]--[@b103-cia-4-121]                                         2 g sachet dissolved in water orally one daily                                VF: 41%\                                                                                                Nausea and diarrhea; possible increase risk for VTE and nervous system disorders; Not recommended if CrCl \< 30 mL/min                                                                                                                                Approved outside the US
                                                                                                                                                                      HF: NS\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                      NVF: 10%(NS)                                                                                                                                                                                                                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Efficacy data from pivotal fracture trials in postmenopausal women.

**Abbreviations:** VF, new morphometric vertebral fracture; NVF, non-vertebral fracture; HF, hip fracture; RRR, relative risk reduction; GI, gastrointestinal; CrCl, creatinine clearance; NR, not reported; NS, not statistically significant; VTE, venous thromboembolism; CEE, conjugated equine estrogen; MPA, medroxyprogesterone acetate; WF, wrist fracture; FDA, Food and Drug Administration; sc, subcutaneous; IU, international units.
